Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?
Related Experiment Video
Updated: Sep 25, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Bruno Vincenzi1, Daniele Santini, Giuseppe Avvisati
1Oncology-Hematology Department, Campus Bio-Medico University, Rome, Italy. brunovincenzi@hotmail.com
Abstract:
Both statins and bisphosphonates may inhibit cancer proliferation by two main different mechanisms: inducing apoptosis along cholesterol synthesis pathway and by antiangiogenic properties. Moreover, also an immunomediated mechanism could be involved in anticancer properties of these molecules. The association of these two drugs could represent an interesting pharmacological approach in anticancer treatment. The available data offer the rationale for future in vitro studies aimed at evaluating proapoptotic and antiangiogenic action of this association. If the results of vitro studies should confirm the hypothesis that statins potentiate the action of bisphosphonates, further clinical investigations could be mandatory to evaluate the efficacy of this new pharmacological approach in anticancer therapy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules